Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLS-010 monotherapy in PD-L1-positive recurrent or metastatic cervical cancer
ChiCTR1900023529Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zimberelimab in Cervical Cancer (CC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
zimberelimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR1900023529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023529.